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Abstract
Background
Pyrosequencing has emerged as an alternative method of nucleic acid sequencing, well
suited for many applications which aim to characterize single nucleotide polymorphisms,
mutations, microbial types and CpGmethylation in the target DNA. The commercially avail-
able pyrosequencing systems can harbor two different types of software which allow analy-
sis in AQ or CpGmode, respectively, both widely employed for DNAmethylation analysis.
Objective
Aim of the study was to assess the performance for DNA methylation analysis at CpG sites
of the two pyrosequencing software which allow analysis in AQ or CpGmode, respectively.
Despite CpGmode having been specifically generated for CpGmethylation quantification,
many investigations on this topic have been carried out with AQ mode. As proof of equiva-
lent performance of the two software for this type of analysis is not available, the focus of
this paper was to evaluate if the two modes currently used for CpGmethylation assessment
by pyrosequencing may give overlapping results.
Methods
We compared the performance of the two software in quantifying DNA methylation in the
promoter of selected genes (GSTP1, MGMT, LINE-1) by testing two case series which
include DNA from paraffin embedded prostate cancer tissues (PC study, N = 36) and DNA
from blood fractions of healthy people (DD study, N = 28), respectively.
Results
We found discrepancy in the two pyrosequencing software-based quality assignment of
DNA methylation assays. Compared to the software for analysis in the AQmode, less per-
missive criteria are supported by the Pyro Q-CpG software, which enables analysis in CpG
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mode. CpG mode warns the operators about potential unsatisfactory performance of the
assay and ensures a more accurate quantitative evaluation of DNA methylation at CpG
sites.
Conclusion
The implementation of CpG mode is strongly advisable in order to improve the reliability of
the methylation analysis results achievable by pyrosequencing.
Introduction
DNAmethylation is an epigenetic modification involved in the regulation of several biological
processes. Methylation of nucleotide bases may lead to N6-methyladenine (6mA), N4-methyl-
cytosine (4mC), and 5-methylcytosine (5mC). While 6mA and 4mC are restricted to prokary-
otes and certain eukaryotes, 5mC is the predominant epigenetic modification in eukaryotic
DNA.
In healthy mature mammalian cells DNA methylation mainly involves a Cytosine when it is
followed by a Guanine (CpG dinucleotides or CpG sites) [1–3]. Most of the mammalian genes
contain CpGs clustered in short regions called CpG Islands and located in the promoter, where
methylation may drive silencing of the gene. Non-CpG methylation may occur within some
immature type of cells (stem cells) at specific stages during development or in some cell tissues
at low proliferative rate (brain, oocytes) [4]. Its functional significance in the mammalian
genome is poorly understood and the mechanism is studied at a lesser extent. On the contrary
dysregulations in the physiological process of CpG methylation are known leading to abnormal
silencing or activation of genes, with potential alteration in cell cycle control and disease onset
[3]. The most relevant pathological outcome of aberrant CpG methylation is cancer, thus
many efforts have been made in recent decades to identify genes affected by aberrant DNA
methylation at CpG sites associated with early carcinogenesis. The analysis of human gene-spe-
cific DNA methylation can be performed under a variety of molecular protocols following
sodium bisulfite modification of the genomic DNA. Sodium bisulfite treatment deaminates the
unmethylated cytosines to uracil whereas leaves unaltered the methylated cytosines [5]. There-
fore methylated and unmethylated DNA sequences become distinguishable using primer/
probe specific PCR, microarray or sequencing mediated methodologies. Several of these meth-
ods are expensive, time consuming, not quantitative, or limited to the measurement of the
methylation status of only one or very few CpG sites [6,7].
Pyrosequencing overcomes these limitations and allows the simultaneous analysis of several
CpG sites up to 100 bp amplicon length [8, 9]. This method is monitored by bioluminescence
and based on DNA sequencing-by-synthesis and luminometric detection of pyrophosphate
release through a series of enzymatic reactions [10–12]. After bisulfite modification of the
genomic DNA, the region of interest is amplified by PCR employing one of the two primers
biotinylated. The amplicon is rendered single stranded and a pyrosequencing primer is
annealed to quantitatively analyse the methylation within the CpG sites of the target sequence.
Nucleotides are added in a predetermined order in each pyrosequencing cycle. Each incorpo-
rated nucleotide event is accompanied by release of pyrophosphate and results in a propor-
tional emission of light. DNA methylation ratios are calculated from the levels of light emitted
by each nucleotide incorporated at the individual CpG positions using a dedicated software.
The results are displayed as an average methylation level for each CpG assayed across all the
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amplification products. The methylation detection limit at individual CpG sites is approxi-
mately 5% [9].
Pyrosequencing is a suitable methodology for the analysis of short DNA sequences such as
those extracted from paraffin-embedded specimens. The pyrosequencing technology benefits
of ease of its implementation, quantitative nature of the results, ability to differentially identify
methylated positions in close proximity. Moreover a low amount (10 ng) of bisulfite-treated
DNA is requested to obtain high reproducibility and to avoid random amplification [13].
Among the commercially available pyrosequencing systems, two models are used for methyla-
tion analyses of candidate genes: PyroMark Q96 and PyroMark Q24 (both purchased by Qia-
gen, Hilden, Germany). They both carry software for analysis in AQ (Allele Quantification)
mode, originally generated for SNP and mutational analysis, and they mainly differ for the
number of testable samples in a run, 96 or 24 respectively. An integrated software was created
for methylation analyses in CpG mode (Pyro Q-CpG™ software v. 1.0.9 and upgrades, Qiagen),
that in the latter system of more recent generation is present by default, while in the former has
to be implemented. However,also the software which allows analysis in AQ (Allele Quantifica-
tion) mode has been recommended for CpG methylation analysis [14, 15] and has been widely
employed for this purpose. Only since 2007 some reports declared the use of the Pyro Q-CpG™
software [16–23]. Several investigations on CpG methylation also recently published have been
performed with AQ mode instead of CpG mode, although proof of equivalent performance of
the two software for this purpose is currently not available.
The present study aims to compare the performance in the quantification of CpG methyla-
tion in human samples of the two software which allow analyses in CpG mode and in AQ
mode respectively, to evaluate if they may give overlapping results
Materials and Methods
Study samples
To compare the performance of the two software for methylation analysis in CpG or in AQ
mode onto two PyroMark Q systems two sets of DNA samples were used, already collected in
the frame of broader studies with their own specific aims approved by the local Ethical Com-
mittee of the San Giovanni Battista Hospital—CTO/CRF/Maria Adelaide Hospital of Turin.
Patient record and information were anonymized and de-identified prior to analysis. The first
set included 36 DNA samples obtained from paraffin embedded prostate cancer tissues of
patients enrolled in a study of association between gene specific methylation and prostate can-
cer mortality, thereafter named “PC study” [24]. This sample series was tested for methylation
status in the promoter of GSTP1 (glutathione S-transferase-pi 1) gene.
The second set included 28 DNA samples obtained from stored buffy coat of healthy volun-
taries involved in a study of association between diet and DNA damage in heavy smokers,
hereafter named “DD study”[25]. This sample series was tested for methylation status in the
promoter of MGMT (O-6-methylguanine-DNA methyltransferase) and LINE-1 (long inter-
spersed nuclear element type-1).
DNA extraction and sodium bisulfite treatment
For the case series including paraffin embedded tissues (PETs) of “PC study”, genomic DNA
was extracted from 3–5 (10 μm thick) sequential sections of PETs through QIAamp DNA
FFPE (Qiagen) according to the manufacturer’s instructions and checked for adequacy by PCR
amplification of the β-globin gene.
Pyrosequencing Performance and DNAMethylation
PLOS ONE | DOI:10.1371/journal.pone.0150483 March 2, 2016 3 / 12
For the case series including stored blood fractions from “DD study”, DNA was obtained
from 100 μl aliquots of buffy coat through QIAamp DNA Blood Mini Kit (Qiagen) according
to the manufacturer’s instructions.
All genomic DNA samples, as well as synthetic controls for methylated and unmethylated
status, underwent bisulfite modification using the Epitect Bisulfite Kit (Qiagen).
Pyrosequencing
Pyrosequencing assays were performed for all the study samples both on a PyroMark Q24
MDx and on a PyroMarkQ96 ID using PyroMark Gold reagents (Qiagen). Primers for GSTP1,
targeting 4 CpGs in the gene promoter, were generated according to PyroMark Assay Design
software version 2.0 (Qiagen). Primers used for the assay of LINE-1, targeting 6 CpGs in the
gene promoter, were chosen according to the literature [26], as well as those for MGMT, target-
ing 6 CpGs in the gene promoter [27]. Primer sequences are listed in Table 1.
PCR reactions were performed in a total volume of 35 μl containing 1X buffer (KCl), 2mM
MgCl2, 200 μM dNTPs, 0.5 μM of each primer, 1.75U Taq polymerase and 6 μl of bisulfte mod-
ified DNA with the following cycling profile: 95°C for 1 min followed by 45 cycles of denatur-
ation at 95°C for 1 min, annealing at the specific temperature for 1 min, extension at 72°C for 1
min. Extension at 72°C for 10 min was finally performed. Amplicons were analyzed by gel elec-
trophoresis on a 2% agarose gel stained with ethidium bromide and visualized by ultraviolet
trans-illumination. The residual PCR product (28 μl for AQ mode, 20 μl for CpG mode) was
added to distilled water (12 μl for AQ mode, 18 μl for CpG mode) and incubated under shaking
with binding buffer pH 7.6 (37 μl for AQ mode, 40 μl for CpG mode) containing 10mM Tris-
HCl, 2 M NaCl, 1mM EDTA, and 0.1% Tween 20, added with sepharose beads (3 μl for AQ
mode, 2 μl for CpG mode) covered by streptavidin. PCR products were washed with ethanol
70%, denatured with NaOH 0.2 M and re-washed with Tris-Acetate 10 mM pH 7.6. Pyrose-
quencing reaction was performed for AQ mode in a total of 45 μl, including 44.82 μl of 20 mM
Tris-Acetate and 5 mMMgAc2, and 0.18 μl of 50 μM sequencing primer (final concentration
0.3 μM); for CpG mode it was performed in a total of 25 μl, including 24.85 μl of 20 mM Tris-
Acetate, 5 mMMgAc2 and 0.15 μl of 50 μM sequencing primer (final concentration 0.3 μM).
Assays were created according to manufacturer’s instruction. The nucleotide dispensation
order was outlined by the software Q24 2.0.
Analytical Software
Pyromark Q96 ID version 1.0.9 software, allowing analysis in AQ mode, was used to generate
and automatically analyze pyrograms resulting from sequencing onto PyroMark Q96 ID
system.
Pyromark Q24 version 2.0 software, allowing analysis in CpG mode, was used to generate
and automatically analyze pyrograms resulting from sequencing onto PyroMark Q24 MDx
system.
Quantitative methylation results were considered both as percentage of individual CpG sites
and as average of the methylation percentage of all the investigated CpGs. Only the latter is
herein reported.
Design of a methylation assay in AQ or in CpG mode mainly differs for two functions
which make the CpG mode more stringent than the AQmode: the first function enables the
insertion of bisulfite controls in the sequence to monitor the complete conversion of the non-
methylated cytosines. The second function concerns the dispensation order: the two modes
include different empty bases as negative controls in specific positions to ensure the accuracy
of the methylation assay.
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Following quantification of the methylation at each CpG site, the quality of the result at
each position is rendered by both the software through a colour-based score: blue, when quan-
tification result is assessed as “passed” therefore acceptable; yellow, when a problem is encoun-
tered in the result interpretation, and the result is graded as “to check”; red, when coexisting
problems lead to hard interpretation of the pyrogram, and the result is assessed as “failed”.
Colour assignment by the software is based on a series of analytical parameters: a coefficient
for height adjustment of the A peak, peaks width, dispensation order, pre-sequencing signal
and baseline drift. A non-compliance with these parameters leads to warning messages.
While in the CpG mode always all the parameters are considered, in the AQ mode the last
two items are never evaluated by default: they can be optionally included by checking the corre-
sponding box. Moreover, the accepted height of the reference peak is quite different: in the
CpG mode a single peak height of more than 20 RLU (relative light units) gives acceptable
results (blue score), between 10 and 20 RLU results have to be checked (yellow score), below 10
RLU results are scored red, meaning that the run height is too low to consider the quantifica-
tion reliable. These parameters can be manually changed by the operator, but they can not be
lowered below 5 RLU. In the AQ mode a similar alert appears, “low signal-to-noise ratio”, but
it does not display numerical and stringent parameters and it only appears when the quantified
signal is too weak to be distinguished from the baseline, that is the signal captured from nega-
tive dispensations. Therefore the AQ mode accepts as “passed” runs with very low pick height,
also below 5 RLU.
Stringency levels (SL), considering the deviation pattern and the deviation sum in variable
positions, are defined in a qualitative way in both modes and set as “normal” by default, but are
modifiable by the user in “low” or “high”. When the pyrogram does not satisfy the normal
stringency level, the following warning messages can appear: uncertain/failed due to high peak
high deviation at dispensation; uncertain/failed due to high sum deviation in variable position;
uncertain/failed surrounding reference sequence pattern.
Statistical analyses
The unweighted kappa statistic were computed by PC-SAS software (version 9.2; SAS Institute,
Cary, NC, USA) to determine the level of chance-adjusted agreement between replicates.
Kappa values of 0.0–0.2, 0.21–0.40, 0.41–0.60, 0.61–0.80, 0.81–0.99, and 1.0 indicate poor,
slight, moderate, substantial, almost excellent, and excellent agreement, respectively [28].
Table 1. Pyrosequencing primer sequences and annealing profile.
Gene Primer Primer sequence PCR annealing T° Target sequence bp CpG sites
GSTP1 sense 5’-GATTTGGGAAAGAGGGAAAGGT- 3’ 50 72 bp 4
antisense Biot-5’-CAAAAAAACGCCCTAAAATCC- 3’
sequencing 5’-GGTTTTTTYGGTTAGTTG-3’
LINE-1 sense Biot-5’-TAGGGAGTGTTAGATAGTGG-3’ Td* 62!55 108 bp 6
antisense 5’–AACTCCCTAACCCCTTAC- 3’
sequencing 5’-AACTCCCTAACCCCTTAC- 3’
MGMT sense 5’- GTATTAGGAGGGGAGAGATT- 3’ Td* 62!59 194 bp 6
antisense Biot-5’-CCTTAATTTACCAAATAACCC- 3’
sequencing 5’-GGGATTTTTATTAAG- 3’
* Td: Touch down
doi:10.1371/journal.pone.0150483.t001
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Agreement was also assessed using plots according to Bland-Altman [29] and Pitman’s test
of difference in variance (STATA 11.1, StataCorp LP, College Station, TX).
Results
GSTP1 methylation analysis employing PyroMark CpG and AQmode
Fig 1 shows the results obtained by testing the “PC study” DNA sample series (N = 36) for
GSTP1 promoter methylation. Methylation analysis was performed for all the samples in
duplicate using the same preliminary PCR products and pyrosequencing profiles, primers
included. Analysis was conducted onto both PyroMark Q96 and a Q24 system, which harbor
the software for quantification in AQ and CpG mode respectively, and which provide their
own software-based quality assessment of the results. Average of methylation percentage of the
4 CpGs investigated in the gene promoter was reported. Deviation between paired samples
analyzed with the two “modes” ranged from 0 to 7.15%. Only one red score warning of inade-
quate quality of the result was assigned by the Q24 software in CpG mode and no red scores
were assigned by the Q96 software in AQ mode. The agreement computed with a threshold
limit of 5% of methylation to distinguish unmethylated from methylated samples was excellent
(k = 1).
Plot according to Bland-Altman (S1A Fig) shows that the two methods gave on average sim-
ilar values (mean difference: -0.66, 95% CI: -1.7 to 0.4) and that the limits of agreement were
not too wide (-7.0 and 5.7).
MGMTmethylation analysis employing PyroMark CpG and AQmode
Fig 2 shows paired results obtained by testing the “DD study” DNA sample series (N = 28) for
MGMT promoter methylation. Methylation analysis was performed for all the samples with
the same approach described for GSTP1. We observed deviation between replicates analyzed
with the two modes ranging between 0 and 14.4%. The concordance obtained by computing
data with the threshold limit of 5% of methylation to distinguish unmethylated from methyl-
ated samples was poor (negative k agreement). The CpG mode generated 14/28 (50%) red
scores, the AQ mode none. Paired samples receiving a red score with CpG mode had a yellow
or even a blue score when using the AQ mode.
Plot according to Bland-Altman (S1B Fig) shows that analyses on MGMT with the two
modes revealed wide limits of agreement (-10.5 to 13.7) and a negative correlation between dif-
ferences and means (p = 0.003).
LINE-1 methylation analysis employing PyroMark CpG and AQmode
Fig 3 shows paired results obtained by testing the “DD study” DNA sample series (N = 28) for
LINE-1 promoter methylation of a template sequence including 6 CpGs. The same methodo-
logical approach described above was used. We obtained a mean percentage of methylation of
70%. Deviation between replicates ranged from 0.5 to 4.2%.
The AQ mode always assigned a blue score to all the 6 investigated CpGs (S2A Fig). Con-
versely, the CpG mode assigned a blue score only to the first investigated CpG in all the sam-
ples (S2B Fig). All the other CpGs in all the samples received a yellow (42% of all tested CpGs)
or a red (57% of all tested CpGs) score.
Plot according to Bland-Altman (S1C Fig) revealed in the methylation analyses on LINE-1
with the two modes a mean difference of 1.0 (95% CI: 0.18 to 1.8). The limits of agreement
(-3.2 to 5.2) have to be considered wide taking into account the small biological variability in
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LINE-1 methylation levels. A negative correlation between differences and means in LINE-1
methylation levels between the two modes is present (p value from the Pitman’s test = 0.006).
Discussion
Pyrosequencing has emerged as an alternative method of nucleic acid sequencing, well suited
for many applications which aim to characterize small DNA target sequences, whereas other
available systems are more commonly used for global DNA analysis approaches (e.g.: microar-
ray-based-GenomeWide Analysis; 454 array-based pyrosequencing platform, Life Sciences—
Roche Diagnostics, Bonn, Germany, Illumina, San Diego, California; MALDI-TOF Mass Spec-
trometry, AB SCIEX Framingham, MA). Single Nucleotide Polymorphisms (SNPs), mutations,
bacteria and viral types, sequences from cDNA library and methylated CpG sites can be effi-
ciently investigated by pyrosequencing [10, 11].
For these applications, and also for DNAmethylation analysis, published results have been
widely obtained also recently by using software for analysis in AQ mode onto the PyroMark
Q96. The use of PyroMark Q24 as well as of software for analysis in CpG mode is more rarely
reported [9, 30–35] although the latter was specifically generated for DNAmethylation assess-
ment. Proof of equivalent performance in CpG methylation analysis of the two software is not
available, and we are not aware of comparison of methylation results from replicates tested
with both software.
Fig 1. GSTP1methylation analysis of DNA samples (PC study) tested in duplicate with PyroMark CpGmode and AQmode.DNA samples (N = 36)
obtained from paraffin embedded prostate tumor tissue of patients involved in “PC study” [24]. Mean methylation percentage of 4 CpGs in the promoter of
GSTP1 gene is reported. Target sequence: 72 bp of GSTP1 promoter (Gene Bank M24485 at position 1001–1072); CpGs at position 1038, 1040, 1043,
1049. Deviation between paired samples ranged from 0 to 7.15%. One red score was assigned by the CpGmode to the sample indicated by the arrow. No
sample has a red score assigned by the AQmode.
doi:10.1371/journal.pone.0150483.g001
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Our paired results obtained with the two “modes” in the GSTP1 methylation analysis were
in agreement. The GSTP1 methylation assay was set up at its best performance, thus reliable
results were obtained with both the analytical systems, supported by blue scores assigned by
the two software. The GSTP1 promoter is usually poorly methylated in normal cells, as the
gene is physiologically expressed, and methylation rate was expected in normal conditions
nearby the assay detection limit [36]. Every increase in the methylation rate can be therefore
interpreted as a modification of the physiological pathway potentially involved in the outcome
under investigation. From this point of view the above reported range of deviation (0–7.15%)
between replicates can be considered within the limits of tolerance, and does not impair the
reliability of the results, nor the conclusions that can be drawn by the analyses.
Conversely, paired results obtained with the two “modes” in the MGMTmethylation analy-
sis were highly discordant. In these assays the deviation between replicates acquires relevance,
because the two modes differently identified methylated and un-methylated samples, weaken-
ing the reliability of the results. While CpG mode highlighted warnings for the interpretation
of these results, likely due to a PCR assay not set up at its best performance yet, the AQmode
passed many results as acceptable with potential impact on the reliability of the final associa-
tion of methylation events with the outcome.
When methylation average differences are supposed to be small among samples of a study
series, accuracy in measuring quantitative results becomes more relevant to support evidence
of associations. Indeed, methylation levels of intersperses sequences (e.g. LINEs) have been
described to be slightly different (<5–10%) between pathological and physiological conditions
[37,38]. LINE sequences are physiologically methylated and are commonly investigated as sur-
rogates of global hypomethylation events. We tested healthy subjects and obtained a mean per-
centage of methylation of 70%, consistent with the blood detection average reported in the
Fig 2. MGMTmethylation analysis of DNA samples (DD study) tested in duplicate onto PyroMark CpGmode and AQmode.DNA samples (N = 28)
obtained buffy coats of patients involved in “DD study” [25]. Mean methylation percentage of 6 CpGs in the promoter of MGMT gene is reported. Target
sequence: 194 bp of MGMT (Gene ID 4255 at position 44526–44719); CpGs at position 44600, 44604, 44607, 44614, 44621, 44623. Deviation between
paired samples ranged from 0.3 to 14.4%. The CpGmode assigned 14 red score. No sample has a red score assigned by the AQmode.
doi:10.1371/journal.pone.0150483.g002
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literature (ranges 66%-82.5% [39,40], 71.9% [41], 73.1% [42], 70–76% [26]). The k agreement
was not assessed as meaningless in this context where, by testing hypomethylation events, we
could only obtain less positive but unlikely negative (i.e. unmethylated) samples. The deviation
between replicates (0.5–4.2%) that we obtained with the two modes could be misleadingly con-
sidered limited. The small biological variability in LINE-1 methylation levels has to be taken
into account as it may potentially underline alterations. The score assignment by the two
modes was very different: a more permissive performance of AQ mode is in contrast with the
strong warnings of CpG mode on the need to improve PCR and pyrosequencing efficiency,
although the assay profile as well as the primer sequences were chosen according to the litera-
ture [26]. If quantization is performed in AQ mode, no alert for potential unreliability of the
results would emerge and risk of wrong classification and incorrect conclusions could not be
excluded.
Both for LINE-1 and MGMT the negative correlation from the Bland-Altman plots trans-
lated into a qualitative change: CpG mode gave higher values for low methylation levels and
lower values than AQ mode for higher methylation levels.
The discrepancy in quality score assignment by the two software modes lies on the different
criteria which represent the stringency level (SL) for the assay: these levels (“low”, “normal”,
“high” SL) are not comparable between AQ and CpG mode. Also if a low SL was manually set
for CpG mode in the aforementioned assay, we would be unable to get acceptable scores for all
CpGs: even the low SL of the CpG mode appeared more stringent than the high SL of the AQ
mode.
Fig 3. LINE-1 methylation analysis of DNA samples (DD study) tested in duplicate onto. PyroMark CpGmode and AQmode.DNA samples (N = 28)
obtained from buffy coats of patients involved in “DD study” [25]. Mean methylation percentage of 6 CpGs in the promoter of LINE-1 gene is reported. Target
sequence: 108 bp of LINE-1 (GeneBank X58075.1 at position 117–224); CpGs at position 156, 131, 165, 167, 172, 182. Deviation between paired samples
ranged from 0.5 to 4.2%. No red scores were assigned by the AQmode. CpGmode assigned blue score only to the first CpG of each sample: all the other
CpG in each samples received red or yellow scores.
doi:10.1371/journal.pone.0150483.g003
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In addition, default acceptable minimum height of single peaks in the pyrogram is quite dif-
ferent in the two modes (CpG: 20 RLU; AQ: none fixed limit), leading to a more stringent iden-
tification of methylation signals from background noise in the CpG mode.
Conclusions
This is, at our knowledge, the first study comparing the performance in quantification of CpG
methylation of the two mode analyses provided by PyroMark systems. Our data show discrep-
ancy in the pyrosequencing software-based quality assignment of methylation results between
the two mode of analyses. The less permissive criteria included into the Pyro Q-CpG™ software
for quantification in CpG mode make explicit unsatisfactory performance of the assays for
quantitative evaluation of DNAmethylation at CpG sites. Therefore, the CpG mode of analysis
ensures a better accuracy in the quantification of DNA methylation compared with the wide-
spread used AQmode. The potential drawbacks emerged in test accuracy could impact on the
reliability of the results, and lead to consider AQ mode as not properly adequate for quantifica-
tion of CpG methylation. Upgraded software versions which include the CpG mode are avail-
able for both Q24 and Q96 instrument. Basing on our data this implementation, in agreement
with previous suggestions [13], is strongly advisable to improve the quality of the CpG methyl-
ation analysis results achievable by pyrosequencing.
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